Top Page
Global Health Limited
(Sydney:GLH)
Global Health Limited (GLH) vs. iShares MSCI Australia ETF (EWA)
Global Health Limited Business Overview & Revenue Model
Global Health Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.67M | 8.67M | 8.12M | 7.82M | 6.54M | 7.03M |
| Gross Profit | 2.10M | 2.10M | -689.94K | -2.18M | -664.00K | 812.71K |
| EBITDA | -792.62K | -793.08K | -1.77M | -7.19M | -1.69M | 57.05K |
| Net Income | -866.88K | -866.63K | -1.31M | -8.05M | -2.05M | -488.00K |
Balance Sheet | ||||||
| Total Assets | 2.84M | 2.84M | 3.08M | 3.12M | 11.03M | 9.04M |
| Cash, Cash Equivalents and Short-Term Investments | 1.38M | 1.38M | 2.07M | 2.24M | 6.38M | 4.84M |
| Total Debt | 1.46M | 1.46M | 1.03M | 44.94K | 141.83K | 304.11K |
| Total Liabilities | 6.58M | 6.58M | 5.98M | 4.74M | 4.95M | 5.00M |
| Stockholders Equity | -3.73M | -3.73M | -2.90M | -1.62M | 6.09M | 4.04M |
Cash Flow | ||||||
| Free Cash Flow | -706.63K | -706.63K | -1.15M | -4.36M | -2.08M | 675.18K |
| Operating Cash Flow | -706.63K | -706.63K | -1.13M | -3.46M | -1.18M | 1.37M |
| Investing Cash Flow | 5.00K | 5.00K | -17.48K | -902.77K | -778.93K | -428.74K |
| Financing Cash Flow | 98.20K | -10.70K | 982.56K | 240.86K | 3.50M | 3.23M |
Global Health Limited Technical Analysis
Global Health Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$12.18M | -1.43 | ― | ― | -40.05% | -49.57% | |
41 Neutral | AU$6.16M | -7.05 | ― | ― | -9.90% | 34.07% | |
41 Neutral | AU$43.43M | -9.29 | -81.30% | ― | -36.68% | 79.41% | |
35 Underperform | AU$4.84M | ― | ― | ― | -67.78% | 37.78% | |
34 Underperform | AU$10.99M | -3.75 | ― | ― | 241.34% | 44.19% | |
33 Underperform | €4.67M | ― | -29.86% | ― | ― | 78.95% |
Global Health Limited Corporate Events
Global Health Limited announced the results of its 2025 Annual General Meeting, where all proposed resolutions were carried. The resolutions included the adoption of the remuneration report, re-election of a director, ratification of the appointment of company auditors, and approval of a 10% placement capacity under ASX Listing Rule 7.1A. These outcomes reflect strong shareholder support and may enhance the company’s operational capabilities and strategic positioning in the digital health sector.
Global Health Limited has announced a change in its company secretary position, with Ms. Eryl Baron resigning and Mr. Chris Fernandes being appointed as the new Joint Company Secretary. This change is effective immediately, with Mr. Fernandes taking responsibility for communication with the ASX regarding Listing Rules Matters. This transition is part of the company’s ongoing efforts to maintain effective governance and communication within the healthcare technology sector.
Global Health Limited held its Annual General Meeting on November 25, 2025, where Group Managing Director Mathew Cherian presented. The company emphasized that it is not offering shares and disclaimed any responsibility for the accuracy or completeness of the information provided. Stakeholders are advised to conduct their own inquiries and seek professional advice if considering acquiring shares, as the company does not guarantee future performance or investment suitability.
Global Health Limited reported its September 2025 quarterly business activity, highlighting significant progress in implementing its MasterCare+ SaaS across new sites and advancing technology upgrades. The company is integrating AI into its operations, resulting in a 10% workforce reduction and enhancing productivity. Despite a delay in R&D refunds affecting cash flow, the company’s EBIT improved by over 25% from the previous year. Global Health is strategically positioned to expand into emerging healthcare segments and home-based care, supported by its modernized technology platforms and AI capabilities, aiming to diversify its business model and extend its market reach.
Global Health Limited has announced its Annual General Meeting (AGM) scheduled for 25 November 2025, encouraging shareholders to participate and submit proxy votes in advance. The company has adapted to new legislative requirements by offering electronic access to meeting documents and updates, reflecting its commitment to modern communication practices and stakeholder engagement.
Global Health Limited has announced the procedures for appointing proxies and voting at their upcoming Annual General Meeting scheduled for November 25, 2025. The announcement details the steps for shareholders to appoint proxies, vote on resolutions, and attend the meeting, emphasizing the importance of timely submission of proxy forms to ensure participation in key company decisions. This meeting will address significant resolutions, including the adoption of the remuneration report, re-election of a director, ratification of the company’s auditors, and approval of a 10% placement capacity, which could impact the company’s governance and financial strategies.
Global Health Limited has announced its Annual General Meeting (AGM) scheduled for November 25, 2025, in Melbourne. The meeting will cover the company’s financial statements, the adoption of the remuneration report, the re-election of director Steven Pynt, the ratification of PKF Melbourne Audit and Assurance Pty Ltd as company auditors, and the approval of a 10% placement capacity under ASX Listing Rule 7.1A. These resolutions are crucial for the company’s governance and operational strategy, impacting shareholder decisions and the company’s future financial and strategic direction.
Global Health Limited announced the cessation of 150,000 performance rights due to unmet conditions, effective October 17, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s operational performance and strategic direction.
Global Health Limited has announced the issuance of 710,000 performance rights under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.
Global Health Limited announced the cessation of 40,000 performance rights due to unmet conditions, effective September 30, 2025. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting on the company’s operational adjustments and strategic focus.
Global Health Limited has announced the quotation of 116,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of an employee incentive scheme. This move is expected to enhance the company’s market presence and provide additional liquidity, potentially benefiting stakeholders by aligning employee interests with company performance.
Global Health Limited has announced a strategic partnership with SafeWork Health, marking its entry into the workplace health sector. This collaboration leverages Global Health’s SaaS ecosystem to enhance pre-employment health screenings, a growing market due to mandated compliance under Work Health and Safety legislation. The partnership positions Global Health to capture recurring revenue opportunities in a high-growth market segment, reinforcing its competitive market position and expanding its services beyond traditional healthcare. SafeWork Health will implement Global Health’s MasterCare+ Client Management System and other digital solutions to improve operational and regulatory processes in occupational health and safety.